@Amanda_Bok @jangeissler @EHA_Hematology @EHC_Haemophilia Spot on! Patients’ attitudes about benefit-risk do change over time with disease progression, and so do naturally the outcomes that matter most. Do you remember the findings from the 2016 study with
111 followers
443 followers
How do you #quantify the #longterm #risksvbeneftis of #medicine Oxidative phosphorylation #oxidativestress https://t.co/X6m7cOdV0J
1,545 followers
Quantifying benefit-risk preferences for new medicines in rare disease patients and caregivers https://t.co/HkQnLyKRbA #ojrd
393 followers
Not surprising pts/caregivers willing to accept more risk|Quantifying benefit-risk for #raredisease drugs https://t.co/fx4o04qu3A #hcmktg